BioArctic
230,2 SEK -0,78%6 investorer følger denne virksomhed
BioArctic is a research company. The greatest business focus is found in the research and development of treatments and antibodies for diseases that affect the nervous system. Examples of various diseases mainly include Alzheimer's and Parkinson's. A large part of the research is carried out in collaboration with researchers at universities and hospitals. The company was founded in 2003 and is headquartered in Stockholm, Sweden.
Omsætning
616 mio.
EBIT %
41,01 %
P/E
88,54
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
NASDAQ Stockholm
BIOA B
Daglig lav / høj pris
213,6 / 236
SEK
Markedsværdi
20,33 mia. SEK
Aktieomsætning
59,01 mio. SEK
Volumen
257 t
Seneste videoer
Finanskalender
Generalforsamling
22.05.2024
Delårsrapport
29.08.2024
Delårsrapport
14.11.2024
Årsrapport
13.02.2025
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
Lars Lannfelt | 33,4 % | 49,2 % |
Pär Gellerfors | 21,6 % | 32,6 % |
Premium
This content is for our Premium customers only.
ViserAlle indholdstyper
BioArctic: Interim Report for the period January - March 2024
BioArctic: Eisai projects Leqembi® revenue to total JPY 56.5 billion for fiscal year 2024 (April 2024 - March 2025)
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools